Objective: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positivepolycythemia vera (PV) and essential thrombocytosis (ET).
Methods: Interferon alpha 2 b was used to treatpatients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study wasto compare rates of hematological and molecular remission.
Results: Patients in the interferon alpha 2 b groupachieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, witha lower incidence of thrombosis.
Conclusion: Compared with hydroxyurea, interferon alpha 2 b could reduceJAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatmentefficacy and reduce complications.